.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Daiichi Sankyo
Fish and Richardson
Cerilliant
Medtronic
Chubb
Harvard Business School
Baxter
Express Scripts
Fuji

Generated: November 24, 2017

DrugPatentWatch Database Preview

FANAPT Drug Profile

« Back to Dashboard

Which patents cover Fanapt, and what generic Fanapt alternatives are available?

Fanapt is a drug marketed by Vanda Pharms Inc and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eighty patent family members in thirty-one countries.

The generic ingredient in FANAPT is iloperidone. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the iloperidone profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-007May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-004May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-003May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-005May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-006May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-005May 6, 2009ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-005May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-005May 6, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-006May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-003May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: FANAPT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-002May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-001May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-006May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-004May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-003May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-005May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-007May 6, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for FANAPT

Drugname Dosage Strength RLD Submissiondate
iloperidoneTablets1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, & 12 mgFanapt5/6/2013

Non-Orange Book Patents for Tradename: FANAPT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,840,727 (4-heteroaryl)-1-[(2,3-dihydro-1H-isoindol-2-yl) alkyl] piperazines and related compounds and their therapeutic utility► Subscribe
5,624,927 N-[4-(heteroaryl)-1-piperazinyl)alkyl]-1,2,3,4-tetrahydroisoquinolines and n-[4(heteroaryl)-1-piperazinyl)alkyl]-1,2,3,4-tetrahydroisoquinolines, related compounds and their therapeutic utility► Subscribe
5,811,430 1[(2-pyrimidinyloxy) alkyl]-4- (heteroaryl) Piperidines and related compounds and their therapeutic utility► Subscribe
5,578,624 Heteroarylpyrrolidines and their use as antipsychotics and analgesics► Subscribe
RE39265Heteroarylpiperidines, and their use as antipsychotics and analgetics► Subscribe
5,571,828 N-[(3-heteroaryl-1-pyrrolidinyl)alkyl]-2,3-napthalimides and related compounds and their therapeutic utility► Subscribe
5,658,911 Heteroarylpiperidines, and their use as antipsychotics and analgetics► Subscribe
5,998,417 N-[(4-heteroaryl-1-piperazinyl) alkyl]phthalimides and related compounds and their therapeutic utility► Subscribe
6,110,938 1-(arylthioalkyl, arylaminoalkyl or arylmethylenealkyl)-4-(heteroaryl)piperidines and related compounds useful as antipsychotics and analgesics► Subscribe
5,776,963 3-(heteroaryl)-1-[(2,3-dihydro-1h-isoindol-2-yl)alkyl]pyrrolidines and 3-(heteroaryl)-1-[(2,3-dihydro-1h-indol-1-yl)alkyl]pyrrolidines and related compounds and their therapeutic untility► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FANAPT

Country Document Number Estimated Expiration
Finland991869► Subscribe
Australia9720798► Subscribe
New Zealand233710► Subscribe
Russian Federation2216545► Subscribe
Japan6108633► Subscribe
Norway304979► Subscribe
Hungary903090► Subscribe
Canada2757717► Subscribe
Czech Republic9401102► Subscribe
European Patent Office0402644► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Chinese Patent Office
Novartis
QuintilesIMS
Julphar
Fish and Richardson
Farmers Insurance
Citi
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot